NO984016L - Ïyeblikkelig frigivelses pH-avhengig fast doseringsform av cisaprid - Google Patents

Ïyeblikkelig frigivelses pH-avhengig fast doseringsform av cisaprid

Info

Publication number
NO984016L
NO984016L NO984016A NO984016A NO984016L NO 984016 L NO984016 L NO 984016L NO 984016 A NO984016 A NO 984016A NO 984016 A NO984016 A NO 984016A NO 984016 L NO984016 L NO 984016L
Authority
NO
Norway
Prior art keywords
cisapride
dosage form
solid dosage
immediate release
dependent solid
Prior art date
Application number
NO984016A
Other languages
English (en)
Norwegian (no)
Other versions
NO984016D0 (no
Inventor
Paul Marie Victor Gilis
Guido Franciscus Smans
Guido Jozef Maria Gijs
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO984016D0 publication Critical patent/NO984016D0/no
Publication of NO984016L publication Critical patent/NO984016L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO984016A 1996-04-23 1998-09-01 Ïyeblikkelig frigivelses pH-avhengig fast doseringsform av cisaprid NO984016L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201078 1996-04-23
PCT/EP1997/001462 WO1997039744A1 (fr) 1996-04-23 1997-03-20 Forme galenique solide de cisapride independante du ph a liberation immediate

Publications (2)

Publication Number Publication Date
NO984016D0 NO984016D0 (no) 1998-09-01
NO984016L true NO984016L (no) 1998-12-23

Family

ID=8223900

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984016A NO984016L (no) 1996-04-23 1998-09-01 Ïyeblikkelig frigivelses pH-avhengig fast doseringsform av cisaprid

Country Status (23)

Country Link
US (1) US6030988A (fr)
JP (1) JPH10510559A (fr)
KR (1) KR100204115B1 (fr)
CN (1) CN1216467A (fr)
AR (1) AR006790A1 (fr)
AT (1) ATE220543T1 (fr)
AU (1) AU720582B2 (fr)
BG (1) BG102812A (fr)
BR (1) BR9708585A (fr)
CA (1) CA2201264C (fr)
CZ (1) CZ332598A3 (fr)
DE (1) DE69713948D1 (fr)
EA (1) EA000804B1 (fr)
EE (1) EE03552B1 (fr)
ID (1) ID16666A (fr)
IL (1) IL125979A0 (fr)
NO (1) NO984016L (fr)
NZ (1) NZ331705A (fr)
PL (1) PL328917A1 (fr)
SK (1) SK144698A3 (fr)
TR (1) TR199802139T2 (fr)
WO (1) WO1997039744A1 (fr)
ZA (1) ZA973449B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20030138485A1 (en) * 1998-01-14 2003-07-24 Daiichi Pharmaceutical Co., Ltd. Disintegrant
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
CN1197574C (zh) 1999-10-20 2005-04-20 卫材株式会社 稳定苯并咪唑化合物的方法
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
DE10164510A1 (de) * 2001-12-20 2003-07-10 Schering Ag Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
EP1321142A1 (fr) * 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
GB2390541A (en) * 2002-07-12 2004-01-14 Reckitt Benckiser Healthcare Medicinal composition comprising fibre or saccharide bulking agents
AU2003276688A1 (en) * 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US8663681B2 (en) * 2005-05-26 2014-03-04 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
CN1935264B (zh) * 2005-09-23 2010-05-05 北京德众万全医药科技有限公司 一种用于缓控释片的含有hpmc的新型复合辅料
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
CN104352465B (zh) * 2014-11-17 2017-04-12 成都新恒创药业有限公司 一种不含二氧化硅的琥珀酸普芦卡必利药物组合物及其制备方法
JP7222063B2 (ja) 2018-07-12 2023-02-14 四川海思科制▲薬▼有限公司 縮合三環性γ－アミノ酸誘導体の組成物及びその調製
CN109394711A (zh) * 2018-11-06 2019-03-01 威海贯标信息科技有限公司 一种酒石酸西尼必利片组合物
US20250378414A1 (en) * 2022-06-15 2025-12-11 Giovan Battista VAROLI Box for the supply of food products for dysphagic users

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
AU4770593A (en) * 1992-07-07 1994-01-31 Sepracor, Inc. Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
CA2139638A1 (fr) * 1992-07-07 1994-01-20 Nancy M. Gray Methodes d'utilisation de la (-) cisapride pour le traitement du reflux gastro-oesophagien et d'autres troubles
WO1995001803A1 (fr) * 1993-07-06 1995-01-19 Merck & Co., Inc. Combinaisons d'agents anti-h2 et d'agents de motilite gastro-intestinale
EP0670160B1 (fr) * 1994-03-01 1999-07-14 Gerhard Dr. Gergely Produit granulaire ou comprimé contenant un système effervescent et un agent actif pharmaceutique, et son procédé de préparation
CH686865A5 (de) * 1994-06-15 1996-07-31 Gergely Gerhard Pharmazeutische Zubereitung mit einem hydrophoben Wirkstoff und einem Brausesystem, sowie Verfahren zur Herstellung der Zubereitung.
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release

Also Published As

Publication number Publication date
BR9708585A (pt) 1999-08-03
EE03552B1 (et) 2001-12-17
TR199802139T2 (xx) 1999-03-22
IL125979A0 (en) 1999-04-11
KR100204115B1 (ko) 1999-06-15
ID16666A (id) 1997-10-30
NO984016D0 (no) 1998-09-01
EA000804B1 (ru) 2000-04-24
CA2201264A1 (fr) 1997-10-23
JPH10510559A (ja) 1998-10-13
EA199800861A1 (ru) 1999-02-25
CN1216467A (zh) 1999-05-12
AU720582B2 (en) 2000-06-08
WO1997039744A1 (fr) 1997-10-30
US6030988A (en) 2000-02-29
BG102812A (en) 1999-05-31
CA2201264C (fr) 1999-08-10
EE9800269A (et) 1999-02-15
DE69713948D1 (de) 2002-08-22
KR970069038A (ko) 1997-11-07
SK144698A3 (en) 1999-05-07
PL328917A1 (en) 1999-03-01
ATE220543T1 (de) 2002-08-15
CZ332598A3 (cs) 1999-01-13
ZA973449B (en) 1998-10-22
AU2290497A (en) 1997-11-12
NZ331705A (en) 1999-11-29
AR006790A1 (es) 1999-09-29

Similar Documents

Publication Publication Date Title
NO984016D0 (no) Ïyeblikkelig frigivelses pH-avhengig fast doseringsform av cisaprid
FI954905L (fi) Kiinteä farmaseuttinen koostumus, joka sisältää täyteainetta, joka kykenee sitomaan vettä
BR9701304A (pt) Formulação de liberação prolongada
DK0922386T3 (da) Sammensætninger med reguleret frigivelse
ATE264677T1 (de) Feste arzneizubereitung enthaltend benzofuranderivate
PT892640E (pt) Composicoes farmaceuticas de micofenolato entericamente revestidas
NO980707D0 (no) Fremgangsmåte til fremstilling av kopolymerer
DK0746310T3 (da) Præparat med styret afgivelse
ID18427A (id) Pengkabut serbuk
ATE253371T1 (de) Formulierungen von clarithromycin mit verlängerter wirkstoff-freisetzung
NO985694D0 (no) Fremstilling av stereoregulerte polymerer
DE69703902D1 (de) Strahlungsempfindliche Zusammensetzung
NO20002126L (no) Formulering med forlenget frigjøring
DK0975348T3 (da) Stabiliserede tibolon-sammensætninger
BR9509565A (pt) Composições orais de liberação prolongada de cisaprida
DE69717034D1 (de) Lippenstift Präparat
ATE232683T1 (de) Mikrokapsel-formulierungen
DK0912603T3 (da) Fremgangsmåde til fremstilling af visse azacyclohexapeptider
NO984035D0 (no) Farmas°ytiske formuleringer med sakte frigivelse inneholdende mizolastin
ID16838A (id) Komposisi dekafluoropentana
DE59708836D1 (de) Stabilisierte monomerenzusammensetzung
EP0914611A4 (fr) Dosage de la leptine
DE69705283D1 (de) Strahlungsempfindliche Zusammensetzung
ID17419A (id) Komposisi dekafluoropentana
DE69615586D1 (de) Polyelektrolyte enthaltende zusammensetzungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application